Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes

Benzer Materyaller

• Deferasirox for managing iron overload in people with myelodysplastic syndrome
  Yazar:: Meerpohl, Joerg J, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome
  Yazar:: Shenoy, Niraj, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Management of iron overload in myelodysplastic syndromes: combined deferasirox and deferoxamine in a patient with liver disease
  Yazar:: Cerchione, Claudio, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Deferasirox, an oral chelator in the treatment of iron overload
  Yazar:: I. Portioli
  Baskı/Yayın Bilgisi: (2013-05-01)
• Update on the use of deferasirox in the management of iron overload
  Yazar:: Taher, Ali, ve diğerleri
  Baskı/Yayın Bilgisi: (2009)